参考文献/References:
[1] Hopps E,Caimi G.Matrix metalloproteinases in metabolic syndrome[J].Eur J Intern Med,2012,23(2):99-104.
[2] Alberti KG,Eckel RH,Grundy SM,et al.Harmonizing the metabolic syndrome:a joint interim statment of the international diabetes federation task forceon epidemiology and prevention:national heart lung,and blood institute; American heart association; world heart federation; international atherosclerosis society; and international assciation for the study of obesity[J].Circulation,2009,120(16):1640-1645.
[3] Cameron AJ,Shaw JE,Zimmet PZ.The metabolic sy-ndrome:prevalence in worldwide populations[J].Endocrinol Metab Clin North Am,2004,33(2):351-375.
[4] Muzzio ML,Berg G,Zago V,et al.Circulating small dense LDL,endothelial injuring factors and fibronectin in healthy postmenopausal women[J].Clin Chim Acta,2007,381(2):157-163.
[5] Lucero D,Zago V,Lopez GI,et al.Does non-alconolic fatty liver impairalterations of plasma lipoproteins and associated factors in metabolic syndrome?[J].Clin Chim Acta 2011,412(7/8):587-592.
[6] Lau DC,Yan HY,Dhillon B.Metabolic syndrome:a ma-rker of patients athigh cardio vascular risk[J].Can J Cardiol,2006,22(suppl B):85B-90B.
[7] Shim K,Jung S,Joo Y,et al.Clinical significance of ti-ssue levels ofmatrix metalloproteinases and tissue inhibitors of metalloproteinases in gastric cancer[J].J Gastroenterol,2007,42(2):120-128.
[8] Johnson JL.Matrix metalloproteinases:influence on smooth muscle cells and atherosclerotic plaque stability[J].Expert Rev Cardiovasc Ther,2007,5(2):265-282.
[9] Lijnen HR.Angiogenesis and obesity[J].Cardiovasc Res,2008,78(2):286-293.
[10] Kandasamy A,Chow A,Ali M,et al.Matrix metalloproteinase-2 and myocardial oxidative stress injury:beyond the matrix[J].Cardiovasc Res,2010,85(3):413-423.
[11] de Nooijer R,Verkleij CJ,von der Thusen JH,et al.Lesional overexpression of matrix metalloproteinase-9 promotes intraplaque hemorrhage in advancedlesions but not at earlier stages of atherogenesis[J].Arterioscler Thromb Vasc Biol,2006,26(2):340-346.
[12] Tarallo S,Beltramo E,Berrone E,et al.Effects of high glucose and thiamine on the balance between matrix metalloproteinases and their tissue inhibitor in vascular cells[J].Acta Diabetol,2009,47(2):105-111.
[13] Derosa G,D'Angelo A,Salvadeo SA,et al.Modification of vascular andinflammation biomarkers after OGTT in overweight healthy and diabetic subjects[J].Microvasc Res,2010,79(2):144-149.
[14] Humphrey JD.Mechanisms of arterial remodeling in hypertension:coupledroles of wall shear intramural stress[J].Hypertension,2008,52(2):195-200.
[15] Ahmed SH,Clark LL,Pennington WR,et al.Matrix metalloproteinases/tissue inhibitors of metalloproteinases:relationship between changes in proteolyticdeterminant of matrix composition and structural,functional and clinical manifestations of hypertensive heart disease[J].Circulation,2006,113(17):2089-2096.
[16] Flamant M,Flacier S,Dubroca C,et al.Role of matrix metalloproteinases in early hypertensive vascular remodeling[J].Hypertension,2007,50(1):212-218.
[17] Singh U,Dasu MR,Yancey PG,et al.Human C-reactive protein promotes oxidized low density lipoprotein uptake and matrix metalloproteinase-9 release in Wistar rats[J].J Lipid Res,2008,49(5):1015-1023.
[18] Miksztowicz V,Muzzio ML,Royer M,et al.Incr-eased plasma activity ofmetalloproteinase 2 in women with metabolic syndrome[J].Metabolism:Clinicaland Experimental,2008,57(11):1493-1496.
[19] Pasarica M,Sereda OR,Redman LM,et al.Reduced adipose tissue oxygenation in human obesity:evidence for rarefaction,macrophage chemotaxis and inflammation without angiogenic response[J].Diabetes,2009,58(3):718-725.
[20] Unal R,Yao-Borengasser A,Varma V,et al.Matrix metalloproteinase-9is increased in obese subjects and decreases in response to pioglitazone[J].J Clin Endocrinol Metab,2010,95(6):2993-3001.
[21] Cheng M,Hashmi S,Mao XB,et al.Relationships of adiponectin and matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio with coronary plaque morphology in patients with acute coronary syndrome[J].Can J Cardiol,2008,24(5):385-390.
[22] Li L,Mamputu JC,Wiernsperger N,et al.Signaling pathways involved inhuman vascular smooth muscle cell proliferation and matrix metalloproteinase-2expression induced by leptin:inhibitory effect of metformin[J].Diabetes,2005,54(7):2227-2234.
[23] Bujak M,Frangogiannis NG.The role of IL-1 in the pathogenesis of heart disease[J].Arch Immunol Ther Exp,2009,57(3):165-176.